Source comparison
Tesamorelin + Ipamorelin Blend Vial Size Comparison
5mg blend (2.5mg + 2.5mg) 5mg total ~15 doses 7–10 days (pilot studies, single-week protocols) Fits entirely within 28-day window with 18-day buffer Moderate. Higher per-mg cost but zero waste for short protocols Best for initial feasibility studies or researc
This comparison does not assign a generated winner or score.
- 5mg blend (2.5mg + 2.5mg)
- 5mg total
- ~15 doses
- 7–10 days (pilot studies, single-week protocols)
- Fits entirely within 28-day window with 18-day buffer
- Moderate. Higher per-mg cost but zero waste for short protocols
- Best for initial feasibility studies or researchers validating dosing tolerance before committing to extended protocols
- 10mg blend (5mg + 5mg)
- 10mg total
- ~30 doses
- 14–21 days (standard two-week cycles)
- Fits within 28-day window with 7–14 day buffer depending on dosing frequency
- High. Optimal cost-per-dose for standard research timelines
- The standard choice for most lipolytic and recovery research. Balances potency preservation, protocol flexibility, and cost efficiency
- 15mg blend (7.5mg + 7.5mg)
- 15mg total
- ~45 doses
- 21–30 days (extended protocols)
- Reaches 28-day stability limit with no buffer; days 29–45 operate in declining potency zone
- Lowest per-mg cost but highest degradation risk in final weeks
- Only appropriate when two staggered 10mg vials are logistically impractical. Requires disciplined cold chain and sterile technique to minimise final-week potency loss